Barinthus Biotherapeutics plc

DB:2AB Stock Report

Market Cap: €34.2m

Barinthus Biotherapeutics Management

Management criteria checks 1/4

Barinthus Biotherapeutics' CEO is Bill Enright, appointed in Aug 2019, has a tenure of 5.75 years. total yearly compensation is $2.36M, comprised of 26.8% salary and 73.2% bonuses, including company stock and options. directly owns 3.08% of the company’s shares, worth €1.05M. The average tenure of the management team and the board of directors is 0.7 years and 5.3 years respectively.

Key information

Bill Enright

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage26.85%
CEO tenure5.8yrs
CEO ownership3.1%
Management average tenureless than a year
Board average tenure5.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bill Enright's remuneration changed compared to Barinthus Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$65m

Dec 31 2024US$2mUS$634k

-US$61m

Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$2mUS$610k

-US$73m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$55m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022US$2mUS$569k

US$5m

Sep 30 2022n/an/a

US$11m

Jun 30 2022n/an/a

-US$1m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$3mUS$474k

-US$51m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$41m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$3mUS$350k

-US$18m

Dec 31 2019US$381kUS$128k

-US$21m

Compensation vs Market: Bill's total compensation ($USD2.36M) is above average for companies of similar size in the German market ($USD492.89K).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.

CEO

Bill Enright (62 yo)

5.8yrs

Tenure

US$2,362,959

Compensation

Mr. William J. Enright, also known as Bill, MBA, has been the Principal Financial Officer of Barinthus Biotherapeutics plc since May 01, 2025. He is an Independent Director of Bullfrog AI Holdings, Inc. fr...

Leadership Team

NamePositionTenureCompensationOwnership
William Enright
CEO, Director & Principal Financial Officer5.8yrsUS$2.36m3.08%
€ 1.1m
Graham Griffiths
Chief Operating Officerless than a yearUS$896.04k0.26%
€ 88.2k
Gemma Brown
Principal Accounting Officerno dataUS$1.11m0%
€ 0
Sarah Gilbert
Co-Founderno dataUS$48.98kno data
Adrian Hill
Co-Founder & Scientific Advisorno dataUS$61.61kno data
Geoffrey Lynn
Chief Scientific Officerless than a yearno data1.59%
€ 542.4k
Leon Hooftman
Chief Medical Officerless than a yearno datano data

0.7yrs

Average Tenure

44yo

Average Age

Experienced Management: 2AB's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
William Enright
CEO, Director & Principal Financial Officer5.8yrsUS$2.36m3.08%
€ 1.1m
Karen Dawes
Independent Non-Executive Director4.3yrsUS$92.57k0.0042%
€ 1.4k
Anne Phillips
Independent Non-Executive Director4.3yrsUS$91.93k0.0074%
€ 2.5k
Robin Wright
Independent Chairman of the Board6.8yrsUS$127.72k0.12%
€ 40.9k
Pierre Armand Morgon
Independent Non-Executive Director7.3yrsUS$97.68k0.026%
€ 8.9k
Alex Hammacher
Non-Executive Director5.3yrsUS$79.15k0.0074%
€ 2.5k
Benoit den Eynde
Member of Scientific Advisory Boardno datano datano data
Mark Tuthill
Member of Scientific Advisory Boardno datano datano data
Joseph C. Scheeren
Independent Non-Executive Director4.2yrsUS$90.65k0.057%
€ 19.5k

5.3yrs

Average Tenure

62yo

Average Age

Experienced Board: 2AB's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 09:14
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Barinthus Biotherapeutics plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Yi ChenH.C. Wainwright & Co.
Matthew HarrisonMorgan Stanley